Matilde Tubertini, Luca Menilli, Celeste Milani, Cecilia Martini, Maria Luisa Navacchia, Marta Nugnes, Manuela Bartolini, Marina Naldi, Daniele Tedesco, Elisa Martella, Andrea Guerrini, Claudia Ferroni, Francesca Moret, Greta Varchi
INTRODUCTION: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer still lacking effective treatment options. Chemotherapy in combination with immunotherapy can restrict tumor progression and repolarize the tumor microenvironment towards an anti-tumor milieu, improving clinical outcome in TNBC patients. The chemotherapeutic drug paclitaxel has been shown to induce immunogenic cell death (ICD), whereas inhibitors of the indoleamine 2,3- dioxygenase 1 (IDO1) enzyme, whose expression is shared in immune regulatory and tumor cells, have been revealed to enhance the anti-tumor immune response...
March 27, 2024: Frontiers in Chemistry